Ompekimig
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Ompekimig
- immunoglobulin anti human macaca fascicularis interleukin 13 human mus musculus monoclonal pf 07296735 κ chain fusion protein with peptide linker ggggs fusion protein with immunoglobulin g1 448 glutamic acid 461 alanine 462 alanine 464 alanine 595 glutamic acid 655 leucine 661 serine anti human macaca fascicularis interleukin 4 human mus musculus monoclonal pf 07296735 γ1 chain cys453 cys230 cys456 cys233 bis disulfide with immunoglobulin g1 225 arginine 238 alanine 239 alanine 241 alanine 413 arginine 432 leucine 438 serine anti human macaca fascicularis interleukin 33 human sprague dawley rat monoclonal pf 07275307 γ1 chain cys218 cys 221 disulfide with immunoglobulin anti human macaca fascicularis interleukin 13 recombinant heavy chain variable constant domain 1 fusion protein with peptide linker epksc cys447 cys218 disulfide with immunoglobulin anti human macaca fascicularis interleukin 4 human mus musculus monoclonal pf 07296735 κ chain cys224 cys213 disulfide with immunoglobulin anti human macaca fascicularis interleukin 33 human sprague dawley rat monoclonal pf 07275307 κ chain cys453 cys230 cys456 cys233 bis disulfide with immunoglobulin g1 225 arginine 238 alanine 239 alanine 241 alanine 413 arginine 432 leucine 438 serine anti human macaca fascicularis interleukin 33 human sprague dawley rat monoclonal pf 07275307 γ1 chain cys218 cys 221 disulfide with immunoglobulin anti human macaca fascicularis interleukin 13 recombinant heavy chain variable constant domain 1 fusion protein with peptide linker epksc cys447 cys218 disulfide with immunoglobulin anti human macaca fascicularis interleukin 4 human mus musculus monoclonal pf 07296735 κ chain cys224 cys213 disulfide with immunoglobulin anti human macaca fascicularis interleukin 33 human sprague dawley rat monoclonal pf 07275307 κ chain
- Immunoglobulin, anti-(human/Macaca fascicularis interleukin 13) (human-Mus musculus monoclonal PF-07296735 κ-chain) fusion protein with peptide linker (GGGGS) fusion protein with immunoglobulin G1 [448-glutamic acid,461-alanine,462-alanine,464-alanine,595-glutamic acid,655-leucine,661-serine] anti-(human/Macaca fascicularis interleukin 4) (human-Mus musculus monoclonal PF-07296735 γ1-chain), (Cys453→Cys230′),(Cys456→Cys233′)-bis(disulfide) with immunoglobulin G1 [225-arginine,238-alanine,239-alanine,241-alanine,413-arginine,432-leucine,438-serine] anti-(human/Macaca fascicularis interleukin 33) (human-Sprague-Dawley rat monoclonal PF-07275307 γ1-chain), (Cys218→Cys-221")-disulfide with immunoglobulin anti-(human/Macaca fascicularis interleukin 13) (recombinant heavy chain variable-constant domain 1) fusion protein with peptide linker (EPKSC), (Cys447→Cys218′′′)-disulfide with immunoglobulin anti-(human/Macaca fascicularis interleukin 4) (human-Mus musculus monoclonal PF-07296735 κ-chain), (Cys224′→Cys213′′′′)-disulfide with immunoglobulin anti-(human/Macaca fascicularis interleukin 33) (human-Sprague-Dawley rat monoclonal PF-07275307 κ-chain) (Cys453→Cys230′),(Cys456→Cys233′)-bis(disulfide) with immunoglobulin G1 [225-arginine,238-alanine,239-alanine,241-alanine,413-arginine,432-leucine,438-serine] anti-(human/Macaca fascicularis interleukin 33) (human-Sprague-Dawley rat monoclonal PF-07275307 γ1-chain), (Cys218→Cys-221”)-disulfide with immunoglobulin anti-(human/Macaca fascicularis interleukin 13) (recombinant heavy chain variable-constant domain 1) fusion protein with peptide linker (EPKSC), (Cys447→Cys218′′′)-disulfide with immunoglobulin anti-(human/Macaca fascicularis interleukin 4) (human-Mus musculus monoclonal PF-07296735 κ-chain), (Cys224′→Cys213′′′′)-disulfide with immunoglobulin anti-(human/Macaca fascicularis interleukin 33) (human-Sprague-Dawley rat monoclonal PF-07275307 κ-chain)
- ompekimig
- Ompekimig
- ompekimig [INN]
- OMPEKIMIG [USAN]
- ompekimig inn
- ompekimig usan
- pf 07264660
- Pf-07264660
- PF-07264660
- CAS registry numbers
- 2981477-39-6
- ChEMBL ID
- CHEMBL6068473
- FDA ingredient codes (UNII)
- 7S9F79AD9Z
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -mig
- Condition
- Dermatitis, Atopic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000274
- Subject identifier
- D003876
- Condition
- Dermatitis
- Highest recorded phase
- 1
- Condition identifier
- HP:0011123
- Subject identifier
- D003872
- Condition
- Inflammation
- Highest recorded phase
- 1
- Condition identifier
- MP:0001845
- Subject identifier
- D007249
- Condition identifier
- EFO_0000274
- Highest recorded phase
- 2
- Condition identifier
- HP_0011123
- Condition identifier
- MONDO_0004980
- Highest recorded phase
- 2
- Condition identifier
- MP_0001845
Trial references
- NCT05995964
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- DualFab anti-IL-13 LC-linker-anti-IL-4 HC; (H)
- Type
- Protein
- Sequence
- DIQMTQSPSSLSASVGDRVTITCKASESVDHFGWSLVHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECGGGGSEVTLRESGPALVKPTQTLTLTCTFSGFSLSNFGEGLSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCEKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCEVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK
- Component
- Glycosylation sites (N)
- Sequence
- 524 $ 301'''
- Component
- Disulfide bridges
- Sequence
- 222'-95' $ 22'''-96''' $ 23''''-88'''' $ 23-92 $ 23''-92'' $ 133''''-193'''' $ 138-198 $ 138''-198'' $ 145'-201' $ 148'''-204''' $ 218-221' $ 224'''-213'''' $ 245-320 $ 265'''-325''' $ 371-427'' $ 371'''-429'' $ 447-218'' $ 453-230''' $ 456-233''' $ 488-548 $ 594-652
- Component
- Single Fab Anti-IL-33 (L'''')
- Type
- Protein
- Sequence
- DIQMTQSPSSLSASVGDRVTITCRASQPIHNHLDWYQQKPGKAPKLLIYFGKNLQEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQYKKGWSFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Single Fab Anti-IL-33 HC; (H''')
- Type
- Protein
- Sequence
- EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMYWVRQAPGKGLEWVAAITPNAGEDYYPESVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGQYYYTKYSLGYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCRKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK
- Component
- DualFab Anti-IL-13 mFd; (M')
- Type
- Protein
- Sequence
- EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVASISSGDTTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARNEGYYFGLTLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC
- Component
- DualFab Anti-IL-4 LC; (L'')
- Type
- Protein
- Sequence
- DIQMTQSPSSLSASVGDRVTITCRASQSVDEEGDSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNKDPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Related records
Trials (3)
- A Preliminary Study to Evaluate PF-07264660 in Healthy Participants
- A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- A Study to Learn More About the Study Medicine PF-07264660 in Healthy Chinese Adult Participants
In development for (2)
- Atopic eczema Phase 2
- Dermatitis Phase 1